In our cohort, MEOX2 immunoreactivity was significantly higher in the subset of EGFR-amplified GBMs (96.7%, 29/30); it was commonly seen in the rest of the GBMs (70.2%, 33/47) and only rarely observed in IDH1mt tumours (5.9%, 2/34) and non-diffuse gliomas (4.3%, 1/23). Here, MEOX2 is linked to neoplasm.